NCT02127697View on ClinicalTrials.gov

Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Asthma
Interventions
DRUG

NVA237

NVA237 capsules for inhalation, delivered via Concept1 once daily

DRUG

Placebo to NVA237

Placebo to NVA237 delivered via Concept1 once daily

DRUG

salbutamol/ albuterol

Taken as rescue medication

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY